Mural Oncology plc (MURA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Mural Oncology plc (MURA) is up 0.0% since the beginning of the year. At $2 per share, MURA is trading 23.2% below its 52-week high of $3.

Mural Oncology plc (MURA) has returned 0.00% so far this year and -22.43% over the past 12 months.

Based on dividend-adjusted daily data since Nov 16, 2023, MURA's average daily return is +0.10%, while the average monthly return is +1.46%. At this rate, an investment would double in approximately 4.0 years.

Historically, 31% of months were positive and 69% were negative. The best month was Apr 2025 with a return of +108.7%, while the worst month was Mar 2025 at -65.8%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.

On a daily basis, MURA closed higher 37% of trading days. The best single day was Apr 15, 2025 with a return of +134.0%, while the worst single day was Mar 25, 2025 at -61.6%.

Mural Oncology plc has an annualized alpha of 10.21%, beta of 0.64, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 17, 2023.

• This stock participated in 256.95% of S&P 500 Index downside but only 12.43% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.64 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MURA ranks 11 for risk / return — in the bottom 11% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Mural Oncology plc (MURA) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Mural Oncology plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Mural Oncology plc was 83.44%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current Mural Oncology plc drawdown is 66.06%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Mural Oncology plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Mural Oncology plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.